Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.71 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.58 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150067 | 0.94 | EGFR (0.75) | EGFRALKLRRK2MAPK15CAMKK2 | |
| SCHEMBL22170292 | 0.91 | EGFR (0.72) | EGFRALK | |
| SCHEMBL19867179 | 0.90 | ALK (0.70) | EGFRALKLRRK2MAPK15CAMKK2 | |
| SCHEMBL19867176 | 0.87 | ALK (0.68) | EGFRALKLRRK2MAPK15CAMKK2 | |
| SCHEMBL21099614 | 0.87 | ALK (0.59) | EGFRALKPTK2 | |
| SCHEMBL21149588 | 0.86 | ALK (0.72) | EGFRALKLRRK2MAPK15CAMKK2 | |
| SCHEMBL19867189 | 0.86 | ALK (0.84) | EGFRALKLRRK2MAPK15CAMKK2 | |
| SCHEMBL21099428 | 0.86 | ALK (0.60) | EGFRALKPTK2 | |
| SCHEMBL21099503 | 0.85 | ALK (0.60) | EGFRALKPTK2 | |
| SCHEMBL19867372 | 0.85 | ALK (0.71) | EGFRALKLRRK2CAMKK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | EGFR 105/4885ALK 1/4885LRRK2 1850/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | EGFR 105/4885ALK 1/4885LRRK2 1850/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | EGFR 105/4885ALK 1/4885LRRK2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.